Evrcore ISI Boosts PT on Walgreens Boots (WBA) to $95; Confidence in Management is Increasing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
Walgreens Boosts Alliance (WBA) PT Raised to $105 at Leerink Partners
July 9, 2015 5:50 PM EDTLeerink Partners analyst David Larsen reiterated his Outperform rating and boosted his price target on Walgreens Boosts Alliance (NASDAQ: WBA) to $105.00 (from $95.00) after the company reported "excellent" F3Q:15 results.
Larsen commented, "Since this is the first quarter with WBA reporting as a single,... More
Walgreen Boots Alliance (WBA) Tops Q3 EPS by 15c; Appoints New CEO; Boosts Dividend
July 9, 2015 7:02 AM EDTWalgreen Boots Alliance (NASDAQ: WBA) reported Q3 EPS of $1.02, $0.15 better than the analyst estimate of $0.87. Revenue for the quarter came in at $28.8 billion versus the consensus estimate of $29.63 billion.
Executive Vice Chairman and CEO Stefano Pessina said, In just six months since the strategic combination that formed Walgreens Boots Alliance, we are beginning to make progress in our operations, as we were able to deliver another strong quarter. Our Retail Pharmacy USA division produced a solid increase in comparable prescriptions filled in the quarter, along with improved retail front-end margins and very good... More
